share_log

JPMorgan Lowers Price Target on Sage Therapeutics to $18 From $23, Maintains Overweight Rating

JPMorgan Lowers Price Target on Sage Therapeutics to $18 From $23, Maintains Overweight Rating

摩根大通将Sage Therapeutics的目标股价从23美元下调至18美元,仍然保持超配评级。
MT Newswires ·  07/12 11:17

Unity Software(U.US) reported fourth-quarter financial results after the market close on Monday. Here's a rundown of the report.Q4 Earnings: Unity said fourth-quarter revenue increased 35% year-over-year to $609 million, beating the consensus estimate of $562.71 million. The company reported a quarterly loss of 66 cents per share.

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发